Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,454JPY
2:00am EDT
Change (% chg)

¥2 (+0.10%)
Prev Close
¥2,452
Open
¥2,456
Day's High
¥2,466
Day's Low
¥2,452
Volume
1,607,600
Avg. Vol
1,823,780
52-wk High
¥2,750
52-wk Low
¥2,192

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond
Tuesday, 25 Oct 2016 09:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology . Under terms of agreement inspirion will receive an upfront payment .Inspiron will also receive milestone payments and royalties under terms of agreement.  Full Article

Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration
Wednesday, 12 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer .Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed.  Full Article

Daiichi Sankyo Co enters into a collaboration with Agonox Inc
Tuesday, 4 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Financial terms of agreement were not disclosed. . Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target .Entered into a strategic collaboration with Agonox, Inc.  Full Article

Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen
Friday, 15 Jul 2016 12:57am EDT 

Daiichi Sankyo Co Ltd <4568.T> : Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036 . Says it plans to issue 6th series unsecured corporate bonds worth 25 billion yen, with coupon rate of 1.200 percent and maturity date on July 25, 2046 .Subscription date on July 15 and payment date on July 25.  Full Article

Amgen and Daiichi Sankyo agree to commercialize Biosimilars in Japan
Wednesday, 13 Jul 2016 09:00pm EDT 

Amgen Inc : Amgen and daiichi sankyo announce agreement to commercialize biosimilars in japan . Under terms of agreement, amgen will remain responsible for development and manufacturing of biosimilars . Daiichi sankyo will file for marketing approval and be responsible for distribution and commercialization in japan . Amgen will have a limited right to co-promote products . Will retain all additional distribution and commercialization rights for biosimilar programs outside of japan . Specific financial terms of agreement were not disclosed .Deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab..  Full Article

UCB's Vimpat gets Japanese approval
Monday, 4 Jul 2016 02:36am EDT 

UCB SA : UCB and Daiichi Sankyo <4568.T> announce Japanese approval of lacosamide (brand name Vimpat) as adjunctive therapy in treatment partial-onset seizures in adult patients with epilepsy . UCB and Daiichi Sankyo will jointly commercialize lacosamide in Japan . ucb will manufacture and supply product; Daiichi Sankyo will manage distribution and book sales in Japan, with both companies promoting lacosamide in Japan .Approval reinforces commitment of both companies to improve lives of people in Japan living with epilepsy.  Full Article

Daiichi Sankyo plans 28 mln shares repurchase
Monday, 20 Jun 2016 04:11am EDT 

Daiichi Sankyo Co Ltd <4568.T> :Says it plans to buy 28 million shares (4.1 percent outstanding) back, for up to 500 million yen, from June 21 to Oct. 28.  Full Article

Daiichi Sankyo to buy back up to 50 bln yen of stock
Monday, 20 Jun 2016 04:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>:Daiichi Sankyo says to buy back up to 4.1 percent of own shares worth 50 billion yen ($480 million).  Full Article

Nektar says co may pay Daiichi $12.5 mln termination payment
Wednesday, 1 Jun 2016 08:23am EDT 

Nektar :In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing.  Full Article

BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug
Wednesday, 1 Jun 2016 08:15am EDT 

Corrects to add dropped words in the second bullet.Nektar Therapeutics : Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Nektar Therapeutics says also entitled to significant double-digit royalties on net sales in Europe . Plans to submit an MAA filing in June 2016 seeking conditional approval from EMA for use of Onzeald .Nektar Therapeutics and Daiichi Sankyo Europe GmbH sign European licensing agreement for Onzeald(TM) (Etirinotecan Pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

More From Around the Web

BRIEF-HTG Molecular says entered into master services agreement with Daiichi Sankyo Company

* Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory